Clinical Trials Logo

Rift Valley Fever clinical trials

View clinical trials related to Rift Valley Fever.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04754776 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

Start date: June 11, 2021
Phase: Early Phase 1
Study type: Interventional

Phase I open label, non-randomised dose escalation study on healthy UK volunteers aged from 18 to 50 years to assess the safety and immunogenicity of ChAdOx1 RVF

NCT ID: NCT04672824 Completed - Rift Valley Fever Clinical Trials

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

Randomised, single blind, placebo - controlled, dose-escalation, phase I clinical trial recruiting healthy adults aged 18-50 years

NCT ID: NCT00869713 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

RVF
Start date: September 2009
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

NCT ID: NCT00584194 Completed - Rift Valley Fever Clinical Trials

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

RVF
Start date: June 2004
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine

NCT ID: NCT00415051 Completed - Rift Valley Fever Clinical Trials

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

MP-12
Start date: August 2006
Phase: Phase 2
Study type: Interventional

This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 years old) will be vaccinated with a single dose of undiluted RVF MP-12, injected into a muscle.

NCT ID: NCT00287014 Completed - Rift Valley Fever Clinical Trials

Rift Valley Fever in Kenya

Start date: March 2006
Phase: N/A
Study type: Observational

The purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya. They will be given a questionnaire, undergo a medical examination that includes an eye exam, and have a 1-teaspoon sample of blood taken from a vein. Participation will take about 3 hours.